London, United Kingdom
Bactobio is a pioneering London-based biotechnology company established in 2020, driving innovation in the biotech sphere by leveraging advanced genomics, machine learning, and bioengineering. Their focus is on culturing the 99% of microbes that have been previously deemed unculturable, unlocking novel chemistries for effective, specific, and biodegradable applications.
Their proprietary technology holds significant promise in discovering new antibiotics to combat severe bacterial infections and facilitating sustainable plant protection solutions, aligning with both medical and industrial needs.
As of April 2023, Bactobio secured a £490.00K Grant investment, bolstering their capacity to advance their groundbreaking research. With its strategic headquarters in the United Kingdom, Bactobio is positioned at the forefront of the biotechnology industry, offering investors a unique opportunity to capitalize on their exclusive access to nature’s vast bioresource.
